Chromogranin A as biomarker in diabetes.
Chromogranin A (CgA) is an established plasma marker of neuroendocrine tumors and has been suggested to also have a role as biomarker in other diseases. Whether CgA has any role as biomarker in diabetes is, however, unresolved, but its widespread distribution in the secretory granules in endocrine tissues including β cells and α cells in pancreas, and the metabolic effects of its peptide fragments suggest that CgA may play a pathophysiological role in diabetes, and thus also be a potential diabetes biomarker. In this review, we summarize the available information on CgA and some of its functional post-translational cleavage products in diabetes, followed by a discussion of its potential as a plasma marker in diabetes and the methodological concerns involved.
Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Kasper
K
Broedbaek
Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Linda
L
Hilsted
D015415:Biomarkers / Q000097:blood*; D053379:Chromogranin A / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000378:metabolism
D015415:Biomarkers; D053379:Chromogranin A; C050836:pancreastatin
Type 1 diabetes; Type 2 diabetes; biomarkers; catestatin; chromogranin A; diabetes; gestational diabetes; insulin sensitivity; pancreastatin; β-cell destruction